Browsing: Back

For early-stage and clinical-stage biopharma companies, finance and accounting functions have evolved dramatically. Adam Mostafa, chief financial officer of Sitryx and chairperson of the recentFinance and Accounting for Bioscienceconference in the heart of Boston biotech, said, “The boundary between accounting and strategy is gone. We opened with a controllership discussion on expense disaggregation and closed…

CRM

Share buybacks matter for many reasons, including earnings-per-share boosts, dilution offsets, tax efficiency, shareholder leverage, and signals of management confidence. They matter much more for big tech companies because the industry is in the midst of a shift that amplifies these signals.